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Introduction: The role of vitamin D in kidney stone disease and its effect on stone formation 
is still controversial. 
Objectives: To find out the possible role of 25(OH) D3 as an intrinsic factor in urinary calcium 
stone formers (SFs; individuals with one episode during the last 5 years and individuals with 
more than one episode during the last 5 years), we investigated the effect of serum levels of 
vitamin D on recurrence of urinary stones in SFs and control subjects (non-SFs). 
Patients and Methods: A total of 30 patients with first episode of urolithiasis (group A) and 30 
patients with more than one episode of urolithiasis during the last 5 years (group B) aged 18 or 
older enrolled in this study and underwent metabolic evaluation including the measurement 
of serum level of 25(OH)D3, parathyroid hormone (PTH), calcium and uric acid. Thirty age 
and sex-matched patients who had never urinary stone episode (non-SFs) were considered 
as control group. The patients in this study were selected among those admitted in Urology 
Department of Kashani hospital during the last year. Individuals excluded from the study 
were subjects with hyperparathyroidism or with the previous history of hyperparathyroidism.
Results: Mean level of 25(OH) D3 was positively correlated with recurrent stone (mean 
19.89 ± 7.6 in the control group versus 47.21 ± 19.77 in the group with the recurrent stone 
disease). The recurrent stone group (SFs) had the higher serum level of 25(OH) D3 than the 
control. No correlation was observed between the serum levels of PTH and 25(OH) D3 (r  = 0. 
13, P  = 0.11) in both control and urinary SFs group. 
Conclusion: High serum level of vitamin D has an important effect on the pathogenesis 
of repeated urolithiasis. High serum levels of 25(OH) D3 were detected in the group with 
recurrent kidney stone disease. But it seems there was no relation between serum level of 
vitamin D3 and one episode of urolithiasis. Based on the results of this study, the high level of 
vitamin D3 may have a significant role in inducing the recurrence of urinary stone. 
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Introduction
Kidney stones are the third common urinary tract disease 
after prostate problems and urinary tract infections 
(1,2). Around 80% to 85% of kidney stones are made 
up of calcium. Several factors can cause the formation 
of different types of urinary stones in patients. These 
factors are including environment, genetics, changes in 
the urinary concentration of crystallized molecules and 
the availability of natural-chemical macromolecules that 
make up the matrix of urinary stones, and also the urinary 
concentration of physiological inhibitors of crystallization 
(3,4). Some studies suggested that the most likely causes 
for increasing prevalence of urinary tract stones are 
changes in people’s lifestyle and dietary choices (4). After 
the formation of the first stone, the possibility of stone 
recurrence is very high. During 5 to 10 years after the first 
stone, its risk may be more than 50% (5,6).
The role of medical treatment is to prevent the growth of 
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older stones or to prevent the formation of new stones. 
These treatments are long-term and should continue 
even throughout patients’ life. On the other hand, it is 
recommended to make a change in the diet and lifestyle to 
prevent the recurrence of stones. This may be painful for 
patients and sometimes it may result in several side effects. 
However, this recommendation is not necessary for half of 
patients who are not at risk of recurrence stone. Hence it 
is necessary to identify patients at higher risk of recurrent 
stones for reducing of treatment costs and increasing of 
patient satisfaction. Vitamin D is a fat-soluble vitamin that 
acts as a pleiotropic hormone as well. Vitamin D undergoes 
sequential hydroxylations and reaches to a final active 
form of 1,25-dihydroxy vitamin D that interacts with 
its nuclear receptor (VDR) to modulate gene expression 
and to exert its biological effects (7). Vitamin D is crucial 
for proper functions of a wide variety of organ systems. 
Additionally, it is the main steroid hormone involved in the 
mineral ion homeostasis. The trend of VDR to connect to 
1,25(OH)2D3 is approximately three times more than its 
tendency for binding to the other vitamin D metabolites. 
In case of vitamin D intoxication, a sharp rise in the 
amount of 25(OH)2D may be occurred due to its direct 
interaction with VDR. Separation of 1,25(OH)2D3 from 
its protein binding can cause an increase in bioavailability 
of the active hormone and lead to hypercalcemia (8). Any 
genetic defects in VDR may cause changes in metabolism 
of calcium and increasing the risk of stone formation. 
Allelic variation in VDR gene can reflect at least agenetic 
component involved in the formation of  urinary tract 
stones (9).
Objectives
Vitamin D3 plays an important role in the metabolism 
of calcium oxalate in the body. It seems that vitamin D3 
has an important role in development and recurrence of 
stones in the urinary tract. Additionally, its measurement 
is easy and relatively inexpensive. To our knowledge, this 
is the first study to compare the serum levels of vitamin D 
in patients with recurrent urinary tract stone compared to 
first stone formers (SFs) and non-SFs.
Patients and Methods
Study population
This cross-sectional descriptive study was performed 
in Kashani hospital, Shahrekord University of Medical 
Science, Shahrekord (January 2014 to January 2015). 
Patient referred to the Urology Department for urinary 
stone intervention was selected for this study. Around 90 
patients were randomly selected. Study populations were 
limited to patients (age ≥18 years) with a history of one or 
more past-history of kidney stone. Patients were selected 
based on the radiographic and sonographic evidence of 
urolithiasis. Healthy subjects who had no urinary stone 
in the radiological and clinical examinations served as 
control. The three groups of 30 individuals aged 18 or older 
enrolled to this study and underwent metabolic evaluation 
including the measurement of serum levels of 25(OH)D3, 
parathyroid hormone (PTH), calcium and uric acid. All 
cases were matched by age, gender, occupation and then 
assigned to one of the three groups; A (patients with the 
first episode of urolithiasis), B (patients with more than 
one episode of urolithiasis during the last 5 years) and C 
(subject without urinary stone). In this study demographic 
questionnaires were used to collect information such as 
age, gender, family history of kidney stones, history of 
urinary tract stones, history of diabetes, hypertension and 
other complications, administration of thiazide diuretics 
and the use of sun care products. The body mass index 
(BMI) was calculated too. 
Serum levels of uric acid, vitamin D3, calcium and PTH 
measured and chemical stone analysis performed. The 
following patients were excluded from this study; patients 
with anatomical abnormalities in urinary tract such as 
medullary sponge kidney, horseshoe kidneys and urinary 
tract obstruction, sarcoidosis, hyperparathyroidism, non-
calcium urolithiasis and non-cooperative patients.
Serum calcium, PTH and vitamin D measurement
Total calcium was assessed using the Roche Diagnostics 
colorimetric assay on a Hitachi 912 analyzer (Roche 
Diagnostics, UK). Intact serum PTH (iPTH) levels were 
assessed by an electrochemiluminescence immunoassay 
(ECLIA) on the Elecsys Module (Roche Diagnostics, UK). 
Vitamin D level of serum was measured with enzyme-
linked immunosorbent assay (ELISA) method using 
OCTEIA 25-hydroxyvitamin D direct ELISA kits. This 
method determines vitamin D level (ng/mL) based on 
polarized light diversion in the range of 1.25 to 150 nm. 
A falsely low or falsely high value of vitamin D may be 
obtained through vitamin D supplementation. Hence, 
patients were asked whether they taken supplementation. 
This was an exclusion from the study.
Ethical issues
The research followed the tenets of the Declaration 
of Helsinki; informed consent was obtained from all 
patients.  This study was approved by Ethics Committee 
of Shahrekord University of Medical Sciences. All 
participants were informed about the objectives of the 
study and assured that the information will remain 
confidential. Participants also signed out consent forms. 
Data analysis
The analysis was conducted in three groups including A 
(patients with the first episode of urolithiasis), B (patients 
with more than one episode of urolithiasis during the last 
5 years) and C (subject without urinary stone). Statistical 
values are shown as means ± standard deviation (SD). 
Mean levels of vitamin D, calcium, uric acid and iPTH 
in all three groups were compared using the unpaired t 
test. Categorical variables were compared using the chi-
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square test and P < 0.05 was considered significant. Data 
were analyzed using SPSS version 20 software (SPSS Inc., 
Chicago, IL).
Results 
In this study, the mean age of the participants (ranging 
from 18 to 64 years old) was 45 ± 12.3 years. The average 
serum levels of iPTH, Ca, vitamin D3 and uric acid were 
36.93 ± 25.98 pg/mL, 9.57 ± 0.68 mg/dL, 29.02 ± 11.68 ng/
mL and 5.3 ± 0.98 mg/dL, respectively. Chi-square analysis 
showed no relationship between gender and the formation 
of urinary tract stones (χ2=0.074, P = 0.964). Table 1 
demonstrates results of group C and A. The mean serum 
levels of vitamin D in groups C and A were respectively, 
19.8 ± 7.6 ng/mL and 19.9 ± 7.6 ng/mL, (P > 0.05; Table 1).
Table 2 demonstrates the results of group A and B. 
Accordingly, to assess laboratory parameters of the group 
with more than one episode of urolithiasis during the 
last five years (B) and the group with the first episode of 
urolithiasis (A) showed, mean of serum levels of vitamin 
D in groups B and A were respectively, 47.21± 19.77 ng/
mL and 19.98± 7.61 ng/mL (P < 0.05; Table 2).
Table 3 demonstrates the results of group B and C. Likewise, 
to investigate of laboratory parameters of the control 
group (C) and the group with more than one episode of 
urolithiasis during the last five years (B), we found mean 
of serum level of vitamin D in group B (47.21 ± 19.77 ng/
ml) was significantly (P < 0.05) higher than that of group 
C (19.98 ± 7.61 ng/mL) (Table 3).
Table 4 demonstrates results in group A+B and C. 
Similarly to analyze laboratory parameters of the control 
group (C) and the group with the episode of urolithiasis 
(A+B) using t test indicated that mean serum levels of 
vitamin D in subjects with episode of urolithiasis (A+B) 
was significantly higher than that of control group (C), 
respectively 34.07 ± 20.36 ng/mL versus 19.89 ± 7.67 ng/
mL (P < 0.05, Table 4).
With the elimination of BMI as a confounding variable 
in this study, we found a significant positive correlation 
between vitamin D and uric acid (P < 0.05, r = 0.25). 
Between serum vitamin D and Ca was also a significant 
correlation (P < 0.05, r = 0.20). However, no significant 
correlation between vitamin D and iPTH was detected 
while its correction tended to be negative (P > 0.05, 
r = -0.13).
Since the increase in BMI may be involved in the formation 
and recurrence of urinary tract stones, we decided to 
analyze the data in two separated categories; BMI below 
24.9 kg/m2 and BMI more than 25 kg/m2. Among the 
participants in this study, 16.5% had BMI less than 24.9 
kg/m2 (40.7% without urinary tract stone and 59.3% with 
urinary tract stone) and 83.5% had BMI more than 25 
kg/m2 (2.5% without urinary tract stone and 94.8% with 
urinary tract stone). As presented in Table 5 for BMI ˃25 
Table 1. The results of laboratory parameters of control group (C) and the group with first episode of urolithiasis (A)
Group 25(OH)D3 (ng/mL ) Uric acid (mg/dL) Ca (mg/dL) iPTH (pg/mL)
C 19.8±7.6 5.02±0.8 9.6±0.5 40.15±27.66
A 19.9±7.6 5.09±1.3 9.4±0.8 33.96±16.88
P value ˃0.05 ˃0.05 ˃0.05 ˃0.05
Table 2. The results of laboratory  parameters of the group with more than one episode of urolithiasis during the last 5 years (B) and the 
group with first episode of urolithiasis (A)
Group 25(OH)D3 (ng/mL ) Uric acid (mg/dL) Ca (mg/dL) iPTH (pg/mL)
A 19.98±7.61 5.08±1.3 9.44±0.8 33.9±21.8
B 47.21±19.77 5.87±1.04 9.83±0.6 36.7±28.4
P value ˂0.05 ˂0.05 ˂0.05 ˂0.05
Table 3. The results of laboratory parameters of the group with more than one episode of urolithiasis during the last five years (B) and 
control group (C)
Group 25(OH)D3 (ng/mL ) Uric acid (mg/dL) Ca (mg/dL) iPTH (pg/mL)
C 19.8±7.6 5.02±0.8 9.6±0.5 40.15±27.66
B 47.21±19.77 5.87±1.04 9.83±0.6 36.7±28.4
P value ˂0.05 ˂0.05 ˂0.05 ˂0.05
Table 4. The results of laboratory parameters of the control group (C) and the group with the episode of urolithiasis (A+B)
Group 25(OH)D3 (ng/mL ) Uric acid (mg/dL) Ca (mg/dL) iPTH (pg/mL)
C 19.89±7.68 5.02±0.85 9.66±0.5 40.15±27.66
A+B 34.07±20.36 5.49±1.25 9.64±0.7 35.38±25.29
P value ˂0.05 ˃0.05 ˃0.05 ˃0.05
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kg/m2, the serum level of vitamin D in the group with the 
episode of urolithiasis (A+B) was significantly higher than 
that of the control group (C) (P < 0.05).
The analysis of tested parameters in participants with BMI 
below 24.9 kg/m2 showed that the serum level of vitamin 
D in the group with the episode of urolithiasis (A+B) was 
higher than that of the control group (C) (Table 6).
Comparing the results of two groups with urinary tract 
stone (A and B) in category below 24.9 kg/m2, we found 
that serum levels of vitamin D in group with more 
than one episode of urolithiasis during the last 5 years 
(48.42±19.8 ng/mL) was higher than that of the group 
with the first episode of urolithiasis (19.68 ± 7.5 ng/mL) 
(P < 0.05) (Table 7).
Discussion
In the present study, evaluation of roles of 1,25(OH)2D3 
in calcium SFs revealed a correlation between levels of 
1,25(OH)2D3 and stone recurrence. We found, levels of 
1,25(OH)2D3 were significantly increased in recurrent 
calcium SFs compared to first SFs and control cases. 
The active form of vitamin D3 –1,25(OH)2 D3 – is the 
most potent stimulator of intestinal calcium absorption. 
Calcitriol acts on bone and kidney in addition to its 
action in increasing intestinal calcium absorption leading 
to a further increase of serum calcium. As we know 
hypercalciuria is the most common abnormality identified 
in calcium SFs. High urinary calcium concentration leads 
to increased urinary saturation of calcium salts and stone 
formation (10).
The relationship between 25(OH) vitamin D3 levels and 
hypercalciuria has been reported in several studies. Berlin 
et al evaluated the effect of vitamin D3 on the levels of 
calcium in the urine of patients with urinary tract stone. 
They reported, the group of patients with high urinary 
calcium excretion also had significantly higher levels of 
25-hydroxyvitamin D3 than the group of patients with 
low calcium excretion (11). Siener et al reported that 
patients with idiopathic hypercalciuria had higher serum 
concentrations of 1,25(OH)2D3 than normocalciuric SFs 
(12). Similarly, they also found that serum 1,25(OH)2D3 
levels in renal SFs were higher than of control group (12). 
In all of the above studies, they did not separate first 
SFs from recurrent SFs. To our knowledge, this is the 
first study related to the role of vitamin D in recurrent 
SFs compared to first SFs. In the present study, a strong 
relationship between 1,25(OH)2D3 and recurrent stone 
formation was found that may be due to higher urinary 
calcium excretion in these patients. Despite no significant 
differences of serum vitamin D3 levels between the control 
group and the group with the first episode of urolithiasis, 
however vitamin D can play an important role in stone 
recurrence in patients with urinary tract stones.
Studies have shown that a subgroup of patients with 
idiopathic hypercalciuria fails to reduce urinary calcium 
excretion under dietary calcium restriction or fasting 
suggesting a primary disorder in renal tubular calcium 
reabsorption (13,14). The underlying mechanism is still 
not clear, although the vitamin D dependent on expression 
of renal CaR might be the cause. Several studies have 
shown that high 1, 25(OH)2D3 concentration associated 
with increased urinary calcium excretion may responsible 
for this condition (15,16). This hypothesis can explain 
high 1,25(OH)2D3 concentration in our patients with 
Table 5. The results of tested parameters in control group (C) and  groups with the episode of urolithiasis (A+B)in category with BMI˃ 25 
kg/m2
Group 25(OH)D3 (ng/mL ) Uric acid (mg/dL) Ca (mg/dL) iPTH (pg/mL)
C 22.81±7.34 4.8±0.8 9.6±0.4 40.47±28.25
A+B 34.31±20.86 5.5±1.2 9.7±0.6 36.36±25.52
P value ˂0.05 ˃0.05 ˃0.05 ˃0.05
Table 6. The results of tested parameters in the control group (C) and the group with the episode of urolithiasis (A+B) in category with 
BMI below 24.9 kg/m2
Group 25(OH)D3 (ng/mL ) Uric acid (mg/dL) Ca (mg/dL) iPTH (pg/mL)
C 15.64±6.2 5.2±0.8 9.7±0.6 39.68±28.21
A+B 29.6±6.25 4.4±1.3 8.3±1.5 17.36±8.49
P value ˂0.05 ˃0.05 ˂0.05 ˃0.05
Table 7. The results of laboratory parameters of the group with more than one episode of urolithiasis during the last 5 years (B) and the 
group with the first episode of urolithiasis (A) in category with BMI below 24.9 kg/m2
Group 25(OH)D3 (ng/mL ) Uric acid (mg/dL) Ca (mg/dL) iPTH (pg/mL)
B 48.4±19.8 5.9±1.02 9.8±0.6 38.35±28.69
A 19.6±7.5 5.1±1.32 9.5±0.7 34.30±22.22
P value ˂0.05 ˂0.05 ˃0.05 ˃0.05
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recurrent stone formation.
Several studies demonstrated the relationship between 
VDR polymorphisms and hypercalciuria in those with 
recurrent urinary tract stones (17,18). In other study, only 
the relationship between serum levels of vitamin D3 and 
the level of calcium in the urine with renal stones have 
been confirmed. However, Kristina et al concluded that 
consuming vitamin D3 supplements did not increase the 
levels of calcium in the urine of vitamin D3 deficient post-
menopausal women without urinary tract stones (19). 
In contrast, Leaf et al described that the consumption 
of vitamin D3 supplements in patients with vitamin D3 
deficiency and urinary tract stone resulted in increasing 
of serum levels of vitamin D3, although the remarkable 
change was not seen in the level of calcium in the urine 
during 24 hours. This study showed that in patients with 
vitamin D3 deficiency and urinary tract stone, no concerns 
regarding the prescription of vitamin D3 supplements 
exists. However, it recommended monitoring the level 
of urine calcium during 24 hours periodically (20). 
Accordingly, Fallahzadeh et al found that serum levels of 
vitamin D3 were higher in the children with urinary tract 
stone compared with control group (21). In accordance 
with the above mentioned studies, our study showed, 
serum levels of vitamin D3 was significantly higher in the 
group with recurrent stone than those who had a urinary 
stone for the first time or the control group. However, the 
study of Tang et al presented serum levels of vitamin D3 
in individuals with urinary tract stone and did not show 
significant a difference compared to control group, but 
they did not separate recurrent from first SFs (22). We 
found no significant difference in serum levels of vitamin 
D3 in the group with urinary stone for the first time in 
comparison with control group. To find the impact of 
vitamin D3 and PTH on calcium levels of urine in patients 
with recurrent urinary tract stone, Tae Kim et al detected 
a relationship between 1,25(OH)D3 levels and serum 
calcium. They found levels of vitamin D3 was higher in 
the group with hypercalciuria and stone recurrence (23). 
However, serum levels of vitamin D3 had no relationship 
with PTH value in patients with recurrent stones. In our 
study also, no association of 1,25(OH)2D3 with PTH in 
SFs was detected. Altered regulation of 1,25(OH)2D3 
rather than PTH might be the primary intrinsic factor for 
the pathogenesis of calcium SFs.
In our study no significant difference in serum vitamin 
D between the control group and first SFs was detected 
but higher serum vitamin D in recurrent SFs suggests the 
limitation of vitamin D supplementation in these group 
of SFs.
Conclusion
This study was aimed to evaluate the impact of serum 
levels of vitamin D on recurrent SFs. In general, individuals 
with urinary tract stones had higher levels of vitamin D3 
compared to the control group. No significant difference 
of serum vitamin D3 in control group (C) compared with 
the group with the first episode of urolithiasis (A) was 
seen. Serum levels of vitamin D3 were significantly higher 
in the group with more than one episode of urolithiasis 
during the last five years (B) compared with the control 
group (C). The results of our study suggested that the 
measurement of the level of vitamin D can be considered 
as one of the effective factors in recurrent urinary tract 
stone to separate the patients who are at higher risk.
Limitations of the study
Our study was conducted on a limited proportion of 
patients. We suggest investigating  calcium levels of urine 
in the future similar studies.
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